HC Wainwright & Co. Reiterates Neutral on Traws Pharma, Maintains $1 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Traws Pharma (NASDAQ:TRAW) with a Neutral and maintains $1 price target.
Stocks · News reference
Ladenburg Thalmann Downgrades Traws Pharma to Neutral
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Traws Pharma Q2 EPS $(0.16) Beats $(0.34) Estimate
Traws Pharma (NASDAQ:TRAW) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.34) by 51.52 percent. This is a 45.45 percent decrease over losses of $(0.11) per share from the
8-K filing — Traws Pharma, Inc. (TRAW)
Filed: 2026-08-14 AccNo: 0001104659-26-097226 Size: 312 KB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
WHO Director-General Ghebreyesus Says He Considers The Cruise Ship-Linked Hantavirus Outbreak To Be Over